Health Canada approves fast-acting mealtime insulin, Fiasp®, for children with diabetes

Novo Nordisk Canada Inc.

Mar 09, 2020, 08:01 ET

Health Canada also expands Fiasp® approval to include insulin infusion pumps

MISSISSAUGA, ON, March 9, 2020 /CNW/ – Fiasp® (insulin aspart injection), a faster acting mealtime insulin, is now approved in Canada for pediatric patients aged 2 years and above giving Canadian families managing type 1 or type 2 diabetes an effective treatment option to support optimal mealtime glucose control.Health Canada has also expanded the approval of Fiasp® (10 mL vials) to include use in insulin infusion pumps for the improvement of glycemic control.

Diabetes is one of the most common chronic diseases among children and youth.2 Managing diabetes can be challenging for parents and caregivers given it is hard to know exactly how much or how quickly their children will eat, making mealtime insulin dosing difficult.3,4,5  Missed meals, illness and increased physical activity without a corresponding reduction in insulin or increase in carbohydrate consumption can lead to significant diabetes management complications for children.6

Read on –>

Print Friendly, PDF & Email